Respiratory adverse effect encompasses pulmonary complications from pharmaceutical use. Chemotherapy-induced pulmonary fibrosis causes progressive dyspnoea. ACE inhibitor-associated cough affects patient adherence. Bronchial hyperresponsiveness increases asthma risk. Respiratory depression from opioids necessitates careful monitoring.
Clinical monitoring detects respiratory changes early. Pulmonary function testing quantitates airflow changes. Imaging surveillance identifies structural changes. Regulatory submissions highlight respiratory risks. Post-approval monitoring identifies respiratory patterns.
General Biopharmaceutical Concepts
Respiratory Adverse Effect
A respiratory adverse effect is an unwanted treatment-related effect involving the respiratory system, including changes in breathing, lung function or airway health.
Continue Exploring
Browse over 900 biopharmaceutical terms across biologics, ADCs, cell & gene therapy, CMC, clinical development and manufacturing.
Browse Glossary →